Korean J Intern Med > Volume 32(2); 2017 > Article |
|
Variable | Good sleeper (n = 58) | Poor sleeper (n = 42) | p value |
---|---|---|---|
Female sex | 35 (60.3) | 34 (81.0) | 0.004a |
Age, yr | 51.0 (44.0–57.0) | 51.0 (46.0–55.0) | 0.507 |
BMI, kg/m2 | 23.0 (21.6–24.3) | 22.0 (20.4–24.4) | 0.349 |
Disease duration, mon | 79.0 (24.0–169.0) | 73.0 (30.0–131.0) | 0.655 |
ESR, mm/hr | 14.0 (5.0–24.0) | 16.5 (10.0–27.0) | 0.206 |
CRP, mg/mL | 0.1 (0.0–0.5) | 0.1 (0.0–0.2) | 0.675 |
Prednisolone dose, mg | 2.5 (2.0–5.0) | 3.2 (2.0–5.0) | 0.889 |
Prednisolone duration, mon | 10.0 (7.0–21.0) | 14.0 (9.0–22.0) | 0.166 |
VAS | 30.0 (10.0–50.0) | 50.0 (30.0–70.0) | 0.005a |
Fibromyalgia | 4 (3.0) | 24 (40.3) | 0.000a |
BDI-2 | 8.0 (4.0–13.0) | 19.0 (9.0–23.0) | 0.000a |
BDQoL | 25 (20.0–28.0) | 18.5 (13.0–23.0) | 0.000a |
BDCAF | |||
Total score | 2.0 (1.0–4.0) | 3.0 (2.0–4.0) | 0.022b |
Headache | 11 (19) | 16 (38.1) | 0.058 |
Oral ulcer | 41 (70.7) | 34 (81) | 0.349 |
Genital ulcer | 7 (12.1) | 15 (35.7) | 0.010b |
Erythema | 12 (20.7) | 7 (16.7) | 0.804 |
Skin pustule | 7 (12.1) | 5 (11.9) | 1.000 |
Arthritis | 16 (27.6) | 15 (35.7) | 0.517 |
Arthralgia | 9 (27.3) | 33 (49.3) | 0.445 |
Eye symptoms | 9 (15.5) | 9 (21.4) | 0.620 |
Nausea/Vomit/Abdominal pain | 10 (17.2) | 7 (16.7) | 1.000 |
Diarrhea/Blood per rectum | 7 (12.1) | 1 (2.4) | 0.165 |
Major vessel involvement | 2 (3.4) | 6 (14.3) | 0.110 |
Nerve involvement | 8 (13.8) | 9 (21.4) | 0.463 |
Values are presented as number (%) or median (range).
BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure; BDCAF, Behcet disease current activity form.
Variable | BDCAF ≤ 5 (n = 83) | BDCAF > 5 (n = 17) | p value |
---|---|---|---|
Age, yr | 51.0 (44.0–56.0) | 49.0 (46.0–56.0) | 0.810 |
BMI, kg/m2 | 22.7 (20.7–24.4) | 21.6 (20.3–25.6) | 0.330 |
Employment status | 0.390 | ||
None | 35 (42.2) | 10 (58.8) | |
Part time | 9 (10.8) | 2 (11.8) | |
Full time | 39 (47.0) | 5 (29.4) | |
Living circumstances | 0.360 | ||
Alone | 6 (7.2) | 3 (17.6) | |
Partner | 77 (91.8) | 14 (82.4) | |
Caffeine | 28 (90.3) | 61 (88.4) | 0.100 |
Alcohol | 15 (48.4) | 13 (18.8) | 0.080 |
Smoking | 12 (14.5) | 1 (5.9) | 0.570 |
Disease duration, mon | 90.0 (35.5–147.0) | 30.0 (16.0–55.0) | 0.008a |
Prednisolone dose, mg | 2.5 (2.0–4.5) | 4.0 (2.0–7.5) | 0.160 |
Prednisolone duration, mon | 12.0 (8.0–24.0) | 9.0 (8.0–10.0) | 0.030b |
ESR, mm/hr | 15.0 (7.0–25.5) | 16.0 (6.0–22.0) | 0.650 |
CRP, mg/dL | 0.1 (0.0–0.3) | 0.0 (0.0–0.1) | 0.020b |
PSQI total score | 7.0 (4.0–11.0) | 10.0 (6.0–12.0) | 0.114 |
Sleep latency | 1.46 (0.2–2.6) | 1.88 (0.8–3.2) | 0.170 |
Sleep duration | 1.57 (0.39–2.6) | 1.65 (0.0–2.0) | 0.770 |
Sleep efficiency | 0.98 (0.0–2.8) | 0.59 (0.0–2.0) | 0.230 |
Sleep disturbance | 1.17 (0.3–2.3) | 1.41 (0.6–2.2) | 0.160 |
Sleep medication | 0.37 (0.0–1.3) | 0.41 (0.0–3.0) | 0.880 |
Sleep quality | 1.46 (0.1–2.3) | 1.82 (0.8–2.7) | 0.110 |
Daytime dysfunction | 1.02 (0.2–2.0) | 1.71 (0.1–2.9) | 0.030b |
VAS | 30.0 (10.0–50.0) | 50.0 (30.0–80.0) | 0.005a |
BDI-2 | 10.0 (5.0–18.0) | 19.0 (15.0–24.0) | 0.008a |
BDQOL | 23.0 (16.5–27.0) | 18.0 (14.0–24.0) | 0.040b |
Values are presented as number (%) or median (range).
BDCAF, Behcet disease current activity form; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PSQI, Pittsburgh sleep quality index; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure.
Variable | Total PSQI | Sleep latency | Sleep efficiency | Sleep duration | Sleep disturbance | Sleep medication | Daytime dysfunction | Sleep quality |
---|---|---|---|---|---|---|---|---|
Age | 0.02 | –0.07 | –0.120 | –0.049 | –0.156 | –0.036 | –0.074 | –0.045 |
Disease duration | –0.09 | –0.02 | –0.035 | –0.060 | –0.145 | –0.115 | –0.012 | –0.103 |
CRP | –0.105 | –0.137 | –0.003 | –0.019 | –0.095 | –0.028 | –0.132 | –0.005 |
ESR | 0.079 | –0.002 | –0.130 | –0.019 | –0.068 | –0.090 | –0.065 | –0.181 |
VAS | 0.35a | 0.21b | 0.28b | 0.25b | 0.28b | 0.03 | 0.28b | 0.36a |
BDI-2 | 0.52a | 0.43a | 0.34a | 0.36a | 0.29a | 0.23b | 0.28b | 0.5a |
BDQoL | –0.45a | –0.36a | –0.33a | –0.29a | –0.31a | –0.2b | –0.3a | –0.39a |
BDCAF | 0.23b | 0.17 | 0.09 | 0.12 | 0.21b | 0.1 | 0.26b | 0.17 |
PSQI, Pittsburgh sleep quality index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure; BDCAF, Behcet disease current activity form.